Reaction
Sinusitis Bacterial reporting signals
As of the last recalculation, Sinusitis Bacterial appears in 1,046 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 167.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 199 | 167.1 | 168.2 |
| Human Immunoglobulin G | 41 | 41.1 | 41.2 |
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 36 | 34.7 | 34.7 |
| Dimenhydrinate | 14 | 26.5 | 26.5 |
| Hydrocortisone Sodium Succinate | 10 | 21.4 | 21.4 |
| Diphenhydramine | 62 | 20.7 | 20.7 |
| Adrenalinum | 41 | 20.4 | 20.4 |
| Infliximab | 173 | 18.7 | 18.7 |
| Posaconazole Delayed-Release | 10 | 18.3 | 18.3 |
| Posaconazole | 13 | 16.1 | 16.1 |
| Epinephrine | 45 | 14.2 | 14.3 |
| Azelastine | 12 | 13.4 | 13.4 |
| Acetaminophen And Codeine | 6 | 9.9 | 9.9 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 5 | 9.6 | 9.6 |
| Dornase Alfa | 5 | 5.1 | 5.1 |
| Nirmatrelvir And Ritonavir | 12 | 4.5 | 4.5 |